1. Materials information
Names
| Name | L-arginine |
|---|
| Synonym | More Synonyms |
|---|
L-arginine Biological Activity
| Description | L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.Target: OthersL-Arginine is an α-amino acid. It was first isolated in 1886. The L-form is one of the 20 most common natural amino acids. At the level of molecular genetics, in the structure of the messenger ribonucleic acid mRNA, CGU, CGC, CGA, CGG, AGA, and AGG, are the triplets of nucleotide bases or codons that code for arginine during protein synthesis. In mammals, arginine is classified as a semiessential or conditionally essential amino acid, depending on the developmental stage and health status of the individual.L-Arginine is associated with a decrease in cardiac index while stroke index is maintained in patients with severe sepsis. Resolution of shock at 72 hours is achieved by 40% and 24% of the patients in the L-Arginine and placebo cohorts, respectively. L-Arginine (450 mg/kg during a 15-minute period) amplifies and sustains the hyperemia (38%) and increases absolute brain blood flow after eNOS upregulation by chronic simvastatin treatment (2 mg/kg subcutaneously, daily for 14 days) in SV-129 mice. |
|---|
| Related Catalog | Signaling Pathways >> Immunology/Inflammation >> NO Synthase Natural Products >> Others Research Areas >> Others |
|---|
| Target | Human Endogenous Metabolite |
|---|
| References | [1]. Tapiero H, et al. I. Arginine. Biomed Pharmacother. 2002 Nov;56(9):439-45. [2]. Bakker J, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004 Jan;32(1):1-12. [3]. Yamada M, et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab. 2000 Apr;20(4):709-17. |
|---|
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|
| Boiling Point | 367.6±52.0 °C at 760 mmHg |
|---|
| Melting Point | 222 °C (dec.)(lit.) |
|---|
| Molecular Formula | C6H14N4O2 |
|---|
| Molecular Weight | 174.201 |
|---|
| Flash Point | 176.1±30.7 °C |
|---|
| Exact Mass | 174.111679 |
|---|
| PSA | 125.22000 |
|---|
| LogP | -1.79 |
|---|
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
|---|
| Index of Refraction | 1.601 |
|---|
| Water Solubility | 148.7 g/L (20 ºC) |
|---|
Toxicological Information
CHEMICAL IDENTIFICATIONCHEMICAL NAME : Arginine, L-
CAS REGISTRY NUMBER : 74-79-3
MOLECULAR FORMULA : C6-H14-N4-O2
HEALTH HAZARD DATAACUTE TOXICITY DATATYPE OF TEST : Cytogenetic analysis
MUTATION DATATEST SYSTEM : Human Lymphocyte
REFERENCE : MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 372,75,1996 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-RUSSIA:STEL 10 mg/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3074 No. of Facilities: 685 (estimated) No. of Industries: 3 No. of Occupations: 14 No. of Employees: 19298 (estimated) No. of Female Employees: 15719 (estimated)
|
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|
| Hazard Codes | Xn: Harmful; |
|---|
| Risk Phrases | R36 |
|---|
| Safety Phrases | S24/25 |
|---|
| RIDADR | NONH for all modes of transport |
|---|
| WGK Germany | 3 |
|---|
| RTECS | CF1934200 |
|---|
| HS Code | 2922499990 |
|---|
Precursor & DownStream
| Precursor 7 | Previous 1/2 Next |
|---|
 CAS#:7200-25-1
DL-Arginine
 CAS#:91000-69-0
Fmoc-Arg-OH
 CAS#:1432516-48-7
benzyl ((S)-1-(...
 CAS#:2304-98-5
Z-ARG(NO2)-OH
|
| DownStream 10 | Previous 1/3 Next |
|---|
![(5S)-5-[(Dimethylamino)methyl]-1-{[hydroxy(methoxy)phosphoryl]oxy }-4,5-dihydro-1H-imidazol-2-amine structure](https://www.chemsrc.com/caspic/232/103170-78-1.png) CAS#:103170-78-1
(5S)-5-[(Dimeth...
 CAS#:34522-32-2
D-(+)-Octopine
 CAS#:63358-47-4
(+)-4-CHLOROTAR...
 CAS#:352-97-6
2-Guanidinoacet...
|
2. Packaging of materials
For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.
For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product.
Or smaller package 1kg/bottle, 10kgs/bottle as request.
3. Shipping & Delivery
Provide door to door service
Suitable for goods under 50kg
Delivery: 3-7 days
Cost: low cost
Provide airport to airport service
Suitable for goods over 50kg
Delivery: 3-14 days
Cost: high cost
Provide seaport to seaport service
Suitable for goods over 100kg
Delivery: 2-45 days
Cost: low cost
4. Contact information
For more details, pls contact us freely.
Email address: Tina@fdachem.com
Mob: 86 15225627621
WhatsApp/Skype/Wechat/LINE: 86 15225627621
China
